Resveratrol treatment decreases SIRT1 and SIRT2 levels. by Mehtap Kilic Eren (591048)

Fig 10 - by Torsten Schober (20485754)

Activation of NMDA receptors with D-serine obviously limited the decrease of p-CREB in the hippocampus of the surviving LPS-treated mice. by Shuibing Zhang (4336402)

Neuronal differentiation is significantly decreased by age in the mouse hippocampal DG. by Joana Gil-Mohapel (462002)

HDM exposure results in increased MIP-2 and decreased IFNα and IL-13. by Jennifer A. Phan (535730)

“…<p>Adult female BALB/c mice were exposed to 25 μg of HDM protein (or control) daily for 10 days. On day 9 they were infected with 1×10⁸ TCID₅₀ HRV-1B or inactivated virus. …”

Propofol increased the number of the hippocampal pyramidal neurons and decreased the expression of the LC3-II protein and the number of lysosomes and autophagosomes in the ischemic... by Derong Cui (326839)

“…<p>I/R was induced by 2-vessel occlusion. Propofol 10, 50, or 100 mg/kg was administrated intraperitoneally and 3-MA (600 nM) was administered intracerebroventricularly 10 min after the onset of ischemia. (1) Sham-operated group (control group, Cont); (2) I/R group; (3) I/R+ 3-MA 600 nmol group; (4) I/R + propofol 10 mg/kg group; (5) I/R + propofol 50 mg/kg group; (6) I/R + propofol 100 mg/kg group; (7) I/R + vehicle (intralipid, 100 mg/kg) group. …”

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

SPARC overexpression promotes AC invasion by decreasing type IV collagen levels in the BM. by Meghan A. Morrissey (2541352)

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Treatment with con-G showed improved neurological scoring and decreased peri-infarct Ca²⁺ microdeposits. by Rashna Balsara (714796)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

A: Top, representative recording of the application, for 10 seconds, of different concentrations of tribendimidine which produces a depolarization (upward movement of the thickest... by Alan P. Robertson (362793)